Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials

Dawed, Adem Y.; Mari, Andrea; Brown, Andrew; McDonald, Timothy J.; Li, Lin; Wang, Shuaicheng; Hong, Mun Gwan; Sharma, Sapna; Robertson, Neil R.; Mahajan, Anubha; Wang, Xuan; Walker, Mark; Gough, Stephen; Hart, Leen M.‘t; Zhou, Kaixin; Forgie, Ian; Ruetten, Hartmut; Pavo, Imre; Bhatnagar, Pallav; Jones, Angus G.; Pearson, Ewan R.; 't Hart, L. M.; Abdalla, M.; Adam, J.; Adamski, J.; Adragni, K.; Allin, K. H.; Arumugam, M.; Atabaki Pasdar, N.; Baltauss, T.; Banasik, K. B.; Baum, P.; Bell, J. D.; Bergstrom, M.; Beulens, J. W.; Bianzano, S.; Bizzotto, R.; Bonneford, A.; Brorsson, C. A.B.; Brown, A. A.; Brunak, S. B.; Cabrelli, L.; Caiazzo, R.; Canouil, M.; Dale, M.; Davtian, D.; De Masi, F. M.; de Preville, N.; Dekkers, K. F.; Dermitzakis, E. T.; Deshmukh, H. A.; Dings, C.; Donnelly, L.; Dutta, A.; Ehrhardt, B.; Elders, P. J.M.; Engel Thomas, C. E.T.; Engelbrechtsen, L.; Eriksen, R. G.; Eriksen, R. E.; Fan, Y.; Fernandez, J.; Ferrer, J.; Fitipaldi, H.; Forman, A.; Franks, P. W.; Frau, F.; Fritsche, A.; Froguel, P.; Frost, G.; Gassenhuber, J.; Giordano, G. N.; Giorgino, T.; Gough, S.; Graefe-Mody, U.; Grallert, H.; Grempler, R.; Groeneveld, L.; Groop, L.; Gudmundsdóttir, V. G.; Gupta, R. G.; Haid, M.; Hansen, T.; Hansen, T. H.; Hattersley, A. T.; Haussler, R. S.; Heggie, A. J.; Hennige, A. M.; Hill, A. V.; Holl, R. W.; Hong, M. G.; Hudson, M.; Jablonka, B.; Jennison, C.; Jiao, J.; Johansen, J. J.; Jones, A. G.; Jonsson, A.

doi:10.1016/S2213-8587(22)00340-0

All Outputs (1)

Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials (2022)
Journal Article
Dawed, A. Y., Mari, A., Brown, A., McDonald, T. J., Li, L., Wang, S., …Jonsson, A. (2023). Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials. Lancet Diabetes and Endocrinology, 11(1), 33-41. https://doi.org/10.1016/S2213-8587%2822%2900340-0

Background: In the treatment of type 2 diabetes, GLP-1 receptor agonists lower blood glucose concentrations, body weight, and have cardiovascular benefits. The efficacy and side effects of GLP-1 receptor agonists vary between people. Human pharmacoge... Read More about Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials.